Headlines
Arrowhead, Novartis in up to $2 billion deal for neuromuscular therapy license
Published by Global Banking & Finance Review®
Posted on September 2, 2025
2 min readLast updated: January 22, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on September 2, 2025
2 min readLast updated: January 22, 2026
Arrowhead and Novartis sign a $2 billion deal for a neuromuscular therapy license, targeting conditions like Parkinson's.
(Reuters) -Arrowhead Pharmaceuticals will get up to $2 billion from Swiss pharma major Novartis for an exclusive worldwide license to the U.S. drugmaker's experimental therapy that targets neuromuscular conditions such as Parkinson's.
Shares of Arrowhead, which has also partnered with Sanofi and GSK, rose about 4% in early trading following the news.
Novartis has been on a deal-making spree in 2025, including buyouts and licensing pacts, as it prepares for looming patent expirations on several blockbuster medicines.
The company has been looking to acquire Avidity Biosciences, a developer of treatments for rare muscle disorders, according to media reports.
Arrowhead will receive $200 million upfront when the deal closes and up to $2 billion in milestone payments and royalties on future sales. Novartis will receive exclusive worldwide rights to the experimental therapy, ARO-SNCA.
The therapy is in preclinical testing and is designed to lower levels of alpha-synuclein, a protein linked to Parkinson's and related disorders.
The companies said they plan to move the program into human trials as soon as possible.
The agreement also covers future projects using Arrowhead's RNA-targeting platform. Financial terms for those were not disclosed.
Novartis will use Arrowhead's platform to develop additional treatments outside the U.S. drugmaker's current pipeline.
(Reporting by Christy Santhosh and Padmanabhan Ananthan in Bengaluru; Editing by Krishna Chandra Eluri and Sriraj Kalluvila)
The deal is valued at up to $2 billion, which includes $200 million upfront and additional milestone payments and royalties.
The therapy targets alpha-synuclein, a protein linked to Parkinson's disease and related disorders, and is currently in preclinical testing.
Novartis plans to move the therapy into human trials as soon as possible and will also use Arrowhead's RNA-targeting platform for additional treatments.
Shares of Arrowhead rose about 4% in early trading following the announcement of the licensing agreement with Novartis.
Arrowhead has also partnered with Sanofi and GSK in addition to its collaboration with Novartis.
Explore more articles in the Headlines category
